Remicade is classified as a tumor necrosis factor (TNF) blocker, a type of biologic drug [1]. It is specifically a monoclonal antibody that targets TNF-alpha, a protein involved in the body's inflammatory response [1][2]. This mechanism of action makes it effective in treating autoimmune diseases characterized by excessive inflammation [1].
What conditions does Remicade treat?
Remicade is prescribed for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis [1][3]. It works by reducing the amount of active TNF-alpha in the body, thereby decreasing inflammation and its associated symptoms [2].
How does Remicade work?
As a TNF blocker, Remicade binds to TNF-alpha, preventing it from attaching to its receptors on cells and triggering inflammatory processes [2]. By neutralizing TNF-alpha, the drug helps to alleviate joint pain and swelling in arthritis, reduce intestinal inflammation in Crohn's disease and ulcerative colitis, and decrease skin and joint inflammation in psoriatic arthritis and ankylosing spondylitis [1][3].
What is the difference between Remicade and other TNF blockers?
Remicade (infliximab) is one of several TNF-blocking medications available. Other TNF blockers include adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), and golimumab (Simponi) [4]. While they all target TNF-alpha, they differ in their molecular structure, how they are administered (e.g., injection vs. infusion), dosing schedules, and approved indications [4]. Remicade is typically administered intravenously by a healthcare professional [1].
When does Remicade's patent expire?
Information regarding patent expiry for specific drugs can be complex and subject to litigation. DrugPatentWatch.com tracks patent information for numerous medications, which can provide details on patent status and expiry dates [5]. This information is crucial for understanding when generic or biosimilar versions of a drug may become available.
Can biosimilar versions of Remicade be made?
Yes, biosimilar versions of Remicade (infliximab) can be developed and approved. Biosimilars are biological products that are highly similar to an already approved biologic medicine, with no clinically meaningful differences in safety, purity, or potency [6]. Several biosimilars for infliximab have been approved in various regions, offering alternative treatment options [6].